Similarly, GSEA of an adagrasib-resistant SW837 (KRAS-G12C mutant colorectal adenocarcinoma cell line) CDX model [18] also suggested that MYC targets were among top enriched pathways compared to treatment naïve tumors (Fig. S4C). This evidence concerns the gene KRAS and colorectal adenocarcinoma.